Immunogenicity of a recombinant human immunodeficiency virus (HIV) - Canarypox vaccine in HIV-seronegative Ugandan volunteers: Results of the HIV network for prevention trials 007 vaccine study

Huyen Cao, P. Kaleebu, D. Hom, J. Flores, D. Agrawal, N. Jones, J. Serwanga, M. Okello, C. Walker, H. Sheppard, R. El-Habib, M. Klein, E. Mbidde, P. Mugyenyi, B. Walker, J. Ellner, R. Mugerwa

Research output: Contribution to journalArticle

56 Scopus citations

Abstract

In the first preventative human immunodeficiency virus (HIV) vaccine study to be carried out in Africa, 40 HIV-seronegative Ugandan volunteers were randomly assigned to receive a canarypox vector containing HIV-1 clade B (env and gag-pro) antigens (ALVAC-HIV; n = 20), control vector containing the rabies virus glycoprotein G gene (n = 10), or saline placebo (n = 10). Cytotoxic T lymphocyte activity against target cells expressing clade A, B, and D antigens was assessed using standard chromium-release and confirmatory interferon-γ enzyme-linked immunospot (ELISPOT) assays. Neutralizing antibody responses to cell line-adapted strains and primary isolates in all 3 clades were also tested. Twenty percent of vaccine recipients generated detectable cytolytic responses to either Gag or Env, and 45% had vaccine-induced HIV-specific CD8+ T cell responses, as measured by the ELISPOT assay. In contrast, only 5% of the control group had vaccine-specific responses. Neutralizing antibodies against primary and laboratory-adapted HIV-1 clade B strains were seen in 10% and 15% of vaccine recipients, respectively, but responses against clades A and D were not detected. Although the immunogenicity of this clade B-based vaccine was low, ALVAC-HIV elicited CD8+ T cell responses with detectable cross-activity against clade A and D antigens in a significant proportion of vaccine recipients.

Original languageEnglish (US)
Pages (from-to)887-895
Number of pages9
JournalJournal of Infectious Diseases
Volume187
Issue number6
DOIs
StatePublished - Mar 15 2003

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immunogenicity of a recombinant human immunodeficiency virus (HIV) - Canarypox vaccine in HIV-seronegative Ugandan volunteers: Results of the HIV network for prevention trials 007 vaccine study'. Together they form a unique fingerprint.

Cite this